Journal Article10.1016/J.CCLET.2019.10.015
Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines
Zeng Liming,Liao Zonglang,Li Wenwei,Qijuan Yuan,Peng Wu,Zhipeng Gu,Zhongqiu Liu,Guochao Liao +7 more
43
TL;DR: A non-covalent glycosylated gold nanoparticles/peptides nanovaccine which is assembled by β-cyclodextrin based host-guest recognitions can generate significant titers of antibodies and improve the therapeutic effect against melanoma, suggesting the immunogenicity of peptide antigens can be improved by loading with this carrier.
read more
About: This article is published in Chinese Chemical Letters. The article was published on 01 May 2020. The article focuses on the topics: Immunogenicity.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Advancements in nanoparticle-based treatment approaches for skin cancer therapy
Leli Zeng,Basan K.S. Gowda,Mohammed Ahmed,Mohammed A.S. Abourehab,Zhe S Chen,Changhua Zhang,Jia Li,Prashant Kesharwani +7 more
TL;DR: In this paper , the role of various inorganic, polymer, and lipid-based nanoparticles in skin cancer therapy with subsequent descriptions of their patents and clinical trials is discussed, followed by their current treatment modalities and associated drawbacks.
Strategies for efficient photothermal therapy at mild temperatures: Progresses and challenges
TL;DR: Recently, low-temperature photothermal therapy (LTPTT), which could inhibit tumor under mild hyperthermia, has been widely investigated by researchers as discussed by the authors, and the established strategies for LTPTT were intensively described.
88
A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy
Liming Zhang,Lingfeng Xu,Yi Wang,Jieyu Liu,Guanghong Tan,Fengying Huang,Nongyue He,Zhuoxuan Lu +7 more
TL;DR: Wang et al. as discussed by the authors reported a facile approach to prepare graphene oxide (GO)-based therapeutic cancer-nanovaccine, which can efficiently induce the maturation of dendritic cells (DCs), the enhancement of antigen cross-presentation ability, and amplification of cytokine production of immune cells.
58
Recent Advances in Nanotechnology for the Treatment of Melanoma.
TL;DR: In this article, the use of different types of nanoparticles, such as vesicles, polymers, metal-based, carbon nanotubes, dendrimers, solid lipid, microneedles, and their combination with immunotherapies and vaccines is discussed.
55
In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy
Yingying Hu,Yingying Hu,Lin Lin,Lin Lin,Zhaopei Guo,Jie Chen,Jie Chen,Atsushi Maruyama,Huayu Tian,Huayu Tian,Xuesi Chen,Xuesi Chen +11 more
TL;DR: A facile and effective combination strategy to combine in situ vaccination and gene-mediated anti-PD therapy, generated by unmethylated cytosine-phosphate-guanine (CpG) and pshPD-L1 gene co-delivery, achieved the synergistic antitumor efficacy in B16F10 tumor-bearing mice.
54
References
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin,Evelyna Derhovanessian,Matthias Miller,Björn-Philipp Kloke,Petra Simon,Martin Löwer,Valesca Bukur,Arbel D. Tadmor,Ulrich Luxemburger,Barbara Schrörs,Tana Omokoko,Mathias Vormehr,Christian Albrecht,Anna Paruzynski,Andreas Kuhn,Janina Buck,Sandra Heesch,Katharina H Schreeb,Felicitas Müller,Inga Ortseifer,Isabel Vogler,Eva Godehardt,Sebastian Attig,Richard Rae,Andrea Breitkreuz,Claudia Tolliver,Martin Suchan,Goran Martic,Alexander Hohberger,Patrick Sorn,Jan Diekmann,Janko Ciesla,Olga Waksmann,Alexandra-Kemmer Brück,Meike Witt,Martina Zillgen,Andrée Rothermel,Barbara Kasemann,David Langer,Stefanie Bolte,Mustafa Diken,Sebastian Kreiter,Romina Nemecek,Christoffer Gebhardt,Christoffer Gebhardt,Stephan Grabbe,Christoph Höller,Jochen Utikal,Jochen Utikal,Christoph Huber,Carmen Loquai,Özlem Türeci +51 more
TL;DR: The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.
2.1K
Designer vaccine nanodiscs for personalized cancer immunotherapy
TL;DR: It is demonstrated that high density lipoprotein-mimicking nanodiscs coupled with antigen (Ag) peptides and adjuvants can markedly improve Ag/adjuvant co-delivery to lymphoid organs and sustain Ag presentation on dendritic cells.
953
A STING-activating nanovaccine for cancer immunotherapy
Min Luo,Hua Wang,Zhaohui Wang,Haocheng Cai,Zhigang Lu,Yang Li,Mingjian Du,Gang Huang,Chensu Wang,Xiang Chen,Matthew R. Porembka,Jayanthi S. Lea,Arthur E. Frankel,Yang Xin Fu,Zhijian J. Chen,Jinming Gao +15 more
TL;DR: A minimalist nanovaccine by a simple physical mixture of an antigen with a synthetic polymeric nanoparticle, PC7A NP, which generated a strong cytotoxic T cell response with low systemic cytokine expression is reported, suggesting generation of long-term antitumor memory.
A facile approach to enhance antigen response for personalized cancer vaccination.
Aileen Weiwei Li,Aileen Weiwei Li,Miguel C. Sobral,Miguel C. Sobral,Soumya Badrinath,Young Jin Choi,Amanda R. Graveline,Alexander G. Stafford,James C. Weaver,Maxence O. Dellacherie,Maxence O. Dellacherie,Ting-Yu Shih,Ting-Yu Shih,Omar Abdel-Rahman Ali,Jaeyun Kim,Kai W. Wucherpfennig,David J. Mooney,David J. Mooney +17 more
TL;DR: The findings from three independent tumour models suggest that the MSR-PEI vaccine approach may serve as a facile and powerful multi-antigen platform to enable robust personalized cancer vaccination.